SEC Form 4 · accession 0001144204-17-063792
Fortress Biotech, Inc. · FBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Avgerinos
Officer — SVP, BIOLOGICS OPERATIONS
Period of report
Nov 29, 2017
Accepted (ET)
Dec 14, 2017 · 8:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001429260
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.001F1 | Nov 29, 2017 | A | 150,000 | $0.00 | A | 409,088 | D | |
| COMMON STOCK, PAR VALUE $0.001F2 | Dec 12, 2017 | S | 25,593 | $3.59 | D | 383,495 | D | |
| COMMON STOCK, PAR VALUE $0.001F2 | Dec 13, 2017 | S | 19,000 | $3.57 | D | 364,495 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of common stock issued to the Reporting Person upon the partial vesting of an award of restricted stock units initially made on July 15, 2015.
- F2Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the sale transactions on December 12, 2017, was $3.53 to $3.72, and the range of prices for the sale transactions on December 13, 2017, was $3.55 to $3.63. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.